SCHEMBL15363256

SCHEMBL15363256

CNS(=O)(=O)N[C@@H]1CCNC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.44
CA12 O43570 2/20 0.39
CA7 P43166 2/20 0.39
CA14 Q9ULX7 2/20 0.39
HDAC4 P56524 1/20 0.36
CA1 P00915 1/20 0.35
NAMPT P43490 1/20 0.34
EPHX1 P07099 1/20 0.33
KDR P35968 1/20 0.33
BRD4 O60885 1/20 0.33
BRD2 P25440 1/20 0.33
BRD3 Q15059 1/20 0.33
BPTF Q12830 2/20 0.31
DPP4 P27487 1/20 0.31
FAP Q12884 1/20 0.31
DPP8 Q6V1X1 1/20 0.31
DPP9 Q86TI2 1/20 0.31
APLNR P35414 2/20 0.31
ALOX5AP P20292 1/20 0.31
FEN1 P39748 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12765369 1.00 KCNH2 (0.44) KCNH2CA12CA7CA14HDAC4
Hydrochloric Acid SCHEMBL28613888 0.86 CA12 (0.46) KCNH2CA12CA7CA14CA1
SCHEMBL22057277 0.79 CA1 (0.50) KCNH2HDAC4CA1NAMPTEPHX1
SCHEMBL14531831 0.79 KCNH2 (0.47) KCNH2CA12CA7CA14HDAC4
SCHEMBL15082232 0.79 CA1 (0.50) KCNH2HDAC4CA1NAMPTEPHX1
SCHEMBL2017404 0.79 KCNH2 (0.47) KCNH2CA12CA7CA14HDAC4
SCHEMBL2411400 0.79 KCNH2 (0.47) KCNH2CA12CA7CA14HDAC4
Hydrochloric Acid SCHEMBL2017130 0.78 KCNH2 (0.45) KCNH2CA12CA7CA14HDAC4
Hydrochloric Acid SCHEMBL22655656 0.78 KCNH2 (0.45) KCNH2CA12CA7CA14HDAC4
Hydrochloric Acid SCHEMBL2598103 0.78 KCNH2 (0.45) KCNH2CA12CA7CA14HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9567304-B2 Quinazolinedione derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2017-02-14 US disclosed
US-9567304-B2 Quinazolinedione derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2017-02-14 US disclosed
EP-2842946-B1 QUINAZOLINEDIONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2016-09-28 EP disclosed
EP-2842946-B1 QUINAZOLINEDIONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2016-09-28 EP disclosed
US-20150141400-A1 QUINAZOLINEDIONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-05-21 US disclosed
US-20150141400-A1 QUINAZOLINEDIONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-05-21 US disclosed
EP-2842946-A1 QUINAZOLINEDIONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2015-03-04 EP disclosed
EP-2842946-A1 QUINAZOLINEDIONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2015-03-04 EP disclosed
WO-2013161853-A1 QUINAZOLINEDIONE DERIVATIVE 中外製薬株式会社 (JP) 2013-10-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141400-A1 QUINAZOLINEDIONE DERIVATIVE PPARD, SLC5A2, PPARG KCNH2 1990/4885CA12 3820/4885CA7 2328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.